Podcasts about perkinelmer

I'm putting a meme in the show notes. It's my second meme ever, so I'm clearly on a roll. As you can see, it's a picture of two kids taking a test; and the one kid is cheating off the other kid. It's a How to Do Spread Pricing test, and the kid with carrier has his eyes all over the PBM kid's test. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Look, this is a thing now, medical spread. And similar to how PBM spreads adds up to millions, billions of dollars, medical spread is not change in the couch cushions. Did you see the lawsuit against Cigna? Cynthia Fisher mentions it in the conversation that follows. Spoiler alert, here's the numbers: Self-insured employer paid $4 million for a claim. In this case, there's a slide on this Cynthia Fisher gave me, by the way, if you want to see all this written out. So, the employer pays $4 million. The provider was paid—drumroll, please—$876,000. I'm pausing so that sinks in: $4 million paid by the employer; $876,000 of that makes it across the trench to the provider. What happened, you may be wondering, to the $3.2 million in the middle there that the self-insured employer wrote a check to their carrier for? If I'm the employer, I think I would sort of want to know where the $3.2 million went, because … yeah. I think anyone would be hard-pressed to explain how a prudent fiduciary is managing to pay millions of dollars of its plan members' money for services that actually cost a fraction of that. And this is just one claim. But you came here for a show about transparency. Why, you may be wondering, am I talking about medical spread pricing? It's not a super far leap, so many of you are probably there already; but let me quote Chris Deacon. She wrote, “As these conglomerates expand control over healthcare delivery and administration, radical transparency is our only bulwark. Patients and employers deserve to know exactly what they're paying for, without hidden fees disguised as care costs.” I don't think anyone would say that transparency alone is sufficient to transform healthcare, but it's definitely a start for sure. So, yeah … transparency. The reason why lawsuits about overpayments, big ones—and there's a bunch of them afoot right now, not just that Cigna one—but the reason that these are going down in the first place is because hospital prices and carrier prices are now somewhat available. And we have some plan sponsors—the ones who are worried about fiduciary duty, at least—these plan sponsors are able to cobble together the math to catch a glimpse of how much money is vanishing. Dollars they and their members are paying for medical claims that never make it to the care team providing the care. And who is shocked? Are you shocked? I'm not shocked. Let me read a sentence from a carrier contract that Justin Leader sent me the other day. Section 6.3: “Claim administrator's compensation for its services under the agreement shall include the difference between the net claim payments reimbursed to the claim administrator by the employer and the net amounts paid to providers by the claim administrator.” Translation: We are allowed to add spread pricing. We are able to arbitrage. We are able to mark up (or whatever you want to call it) by any amount we want, and you, plan sponsor, just signed up to pay for it. So, that happened. Listen to episode 433 with Justin Leader, by the way. The show is called “The Mystery of the Weekly Claims Wire,” otherwise known as the Not Transparent Weekly Claims Wire. So, look … transparency: We can talk about it in terms of medical prices. We can talk about transparency in terms of contracts. And actually also in terms of quality, but we don't get into that today. Bottom line, plan sponsors need enough access to billing data and hospital prices to calculate how much the middle folks are taking in spread, which is, as aforementioned, quite a thing. For more actual data on the magnitude of spread pricing goings-on, ask Dan Ross. That's my suggestion. He's got spreadsheets he can show you of how much plan sponsors are paying and how much providers are charging and how much is going missing in the middle. For even more on this, read the recent Owens & Minor lawsuit that just got filed, which is just a case study in how hard some of these middlemen/carrier entities are working to obscure and hide what they are doing. Because, yeah, sunshine is a great disinfectant, and that's what transparency is. Sunshine. Here's another interesting link from Chris Deacon. I say all this to say, this is the kind of transparency that Cynthia Fisher and I talk about in the show today: contract transparency, bill charges transparency, and hospital or medical price transparency for plan sponsors. We do not get into today consumers or patients using price information to shop, just FYI. We also do not get into, really, price convergence, which is what happens when hospital and carrier prices become available in a market and is often brought up on or about conversations about transparency. Okay, I will say just one thing about price convergence. There was some chatter in anti-transparency press releases from parties mostly that didn't want to be transparent at all, no way no how. But there was some talk a couple of years ago that if contracted prices became transparent, the healthcare industry would raise their prices to match the highest in the market and the result would be rising healthcare prices and greater total costs. That turns out, it seems, to be false. There's a study that shows that the bottom of the market (those with the cheapest prices) do, in fact, raise their prices but not as much as the top of the market lowers theirs. So, there is actually net savings. Read about the Turquoise Health study and an article that Forrest Xiao and team posted that shows this, and it's the first study of its kind, at least that I have seen. Okay, so contract transparency, data transparency, that's what's on deck to discuss today with Cynthia Fisher, as I have mentioned several times already, who has a long history as an entrepreneur in the healthcare space. So, Cynthia Fisher gets U.S. healthcare, and she gets being a plan sponsor and a fiduciary. She is founder and chairman of PatientRightsAdvocate.org, as well as Power to the Patients. Her focus is on ensuring that all healthcare shows prices up front so that we can have accountability and integrity in billing and at any point of care. Cynthia has said early and often that transparency protects the ultimate purchasers of healthcare—meaning plan sponsors, plan members, and patients—from overcharges, spread pricing, or otherwise. Where there's mystery, there is margin, as Anthony Ciaccia has said often. Cynthia's call to action is as follows, but listen to the show to hear her say it more eloquently. C-suites, CFOs, in-house counsel use purchasing discipline that your company probably uses elsewhere in the procurement of health benefits.  Cynthia Fisher also says as part of the call to action, refuse to sign blank checks to the healthcare industry and refuse anti-audit provisions. She also has a call to action for the accounting industry to stop ignoring auditing the health plans. And this matters just given the bald-faced fact right now that overcharges are party sized. Let me wrap up with this: There's a lot of brute force tactics out there being deployed by some plan sponsors that effectively keep plan members from getting the care they need because they are functionally uninsured. I've done multiple shows on this, and I link to some of them below. I just can't help to think, some of this brute force, you know, high-deductible health plans and some pretty savage cost containment strategies, might be unnecessary if middleman excess profits were eliminated. Well, I say this with some evidence, actually. Andreas Mang (EP419) was on the pod. He talked about saving 15% or more by being smart about contracts and plan assets at the financial and purchasing level. Brian Uhlig … was talking to him the other day. He was telling me he saved $80 million just doing contracts right. Also Claire Brockbank (EP453) talks about this; Cora Opsahl (EP452), too, from 32BJ. Those are two recent shows, again, about how much money can be saved by only signing contracts that ensure transparency. Also mentioned in this episode are Patient Rights Advocate, Chris Deacon, Justin Leader, Dan Ross, Forrest Xiao, Anthony Ciaccia, Andreas Mang, Brian Uhlig, Claire Brockbank, Cora Opsahl, Mark Cuban, and Mark Cuban Cost Plus Drug Company.   You can learn more at PatientRightsAdvocate.org.    Cynthia A. Fisher is founder and chairman of PatientRightsAdvocate.org, a nonprofit organization seeking healthcare price transparency, giving power to American consumers—patients, employers, and unions—to lower their costs of care and coverage through a functional marketplace and choice. Cynthia is best known for her pioneering work as founder and CEO of ViaCord, Inc., a leading price-transparent umbilical cord blood stem cell banking company which she started in 1993. In 2000, she co-founded and was president of the cellular medicines company ViaCell, Inc., of which ViaCord became a division. ViaCell went public in 2005, was acquired by PerkinElmer, and exists today under the ViaCord brand. Cynthia also serves on the public company boards of the Boston Beer Company, Inc. and Easterly Government Properties, Inc. She serves on the Florida Council of 100 and the board of the National Park Foundation, and she previously served on the board of directors of Water.org. Cynthia holds an MBA from Harvard Business School and a bachelor's and honorary Doctorate of Science degree from Ursinus College.   09:03 What is the goal of PatientRightsAdvocate.org? 10:28 Is American competitiveness being affected by healthcare spend? 13:47 Why is transparency a root cause to healthcare costs? 15:11 What's going on across the country to empower transparency in healthcare? 19:31 “I think people are fed up.” 21:22 The Cigna lawsuit in California. 26:36 How do employers navigate contracts against anti-steering? 28:54 EP419 with Andreas Mang. 29:33 EP452 with Cora Opsahl and EP453 with Claire Brockbank. 29:45 EP433 with Justin Leader.   You can learn more at PatientRightsAdvocate.org.   Cynthia A. Fisher of @PtRightsAdvoc discusses #medicalspreadpricing and #contracttransparency on our #healthcarepodcast. #healthcare #podcast #pharma #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW40), Mark Cuban and Ferrin Williams (Encore! EP418), Rob Andrews (Encore! EP415), Brian Reid, Dr Beau Raymond, Brendan Keeler, Claire Brockbank, Cora Opsahl, Dan Nardi, Dr Spencer Dorn (EP451)  

Part 3 of 3. My guest for this week's episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

The state prefers selling stakes in state-owned companies to strategic investors over public share sales, Prime Minister said. He added that the government has a clear plan for securing US dollars for a year. He declared that Egypt can sell stakes in companies outside the list of 32 announced earlier.Egypt is expanding the number of ways to acquire citizenship.Ministers approved the latest round of social support measures aimed at mitigating the impact of inflation. The program will raise public-sector wages and pensions and provide tax relief by raising the income tax exemption threshold starting April 2023.Bread and food subsidies are costing the government an extra EGP54 billion, and it will pay out EGP45 billion in fuel subsidies, the Prime Minister said.China Energy could start working on a USD5.1 billion green hydrogen facility in Egypt in May.Balance of payments surplus reached USD523.5 million during 1Q22/23 supported by a 20% decline in current accounts. Trade deficit declined by 18% to USD9 billion due to a 5.1% increase in non-petroleum exports coupled with a 9.9% decline in imports. Goods exports increased by 12.6% to USD10 billion. External debt declined by 0.05% to USD155 billion at the end of September 2022. Foreign investments in T-bills increased by 24% MoM to USD8.04 billion in December.The CBE did not introduce new ATM withdrawal fees, putting an end to rumors that it raised withdrawal fees to EGP20-50. CBE has issued new regulations allowing contactless card payments via mobile apps. Banks are expected to roll out the services to support these payments soon.Brent crude futures shed 3.4% to settle at USD83.29/bbl.EGX head announced a plan to list a new oil services company on the EGX during the coming month.We remind you that EGTS's next court date for the 20.0 million sqm third phase Sahl Hasheesh land plot lawsuit is, if not further postponed, on 11 March 2023.Elevate Capital's healthcare investment platform is looking to acquire a 70-80% stake (not 100% as reported yesterday) in Nile Scan & Labs.Scope, Oxide Chemicals, and Vacsera will set up a JV to build, manage, and operate a factory for biodegradable syringes and other medical supplies. The factory will be built at a cost of USD10 million at Vacsera's industrial complex.PerkinElmer and HVD Life Sciences Egypt will partner with the government to build a beta thalassemia screening lab.Infiniti Company for Vehicles Manufacturing intends to manufacture cars locally by investing around EGP1 billion, with the aim of starting production in 3Q23.

Can rapid whole genome sequencing (WGS) be utilized in the NICU setting? We explore in this podcast episode! Joining us for this episode is Dr. Hong Li, a clinical geneticist at Emory University. Our other expert is a recurring guest, world-renowned geneticist Dr. Madhuri Hegde. She serves as the Senior Vice President and Chief Scientific Officer of Global Lab Services at PerkinElmer Genomics, a global leader in genetic and genomic testing focused on rare diseases, inherited disorders, newborn screening, and hereditary cancer.If you want to hear her on other episodes of DNA Today tune into Episode 177 where we nerded out about the power of whole genome sequencing (which is a great precursor to this conversation) and Episode 202 about Duchenne Muscular Dystrophy.In addition to her role at PerkinElmer, Dr. Hegde is also a board certified diplomate in clinical molecular genetics by the American Board of Medical Genetics, and an ACMG Fellow. Previously, she was the Executive Director of Emory Genetics Laboratory. She received a B.Sc. and M.Sc. from the University of Bombay and a Ph.D. from the University of Auckland. She completed postdoctoral studies at Baylor College of Medicine.Dr. Hong Li is a clinical and biochemical geneticist at Emory University School of Medicine who is passionate about diagnosing and treating children and families with genetic and metabolic diseases. She also oversees the Emory Metabolic Clinic, serves as Co-Chair of the Georgia Newborn Screening Advisory Committee (NBSAC), where she is extensively involved in Georgia's NBS development, implementation, and clinical follow-up for children with metabolic disorders, is the Vice-Chief of the genetics section at Children's Healthcare of Atlanta and geneticist of the multidisciplinary differences of sex development (DSD) clinic at CHOA and the site PI of the DSD translational research network (DSD-TRN). She also serves as the medical director of the Emory CTCF-related disorder (CRD) center.Dr. Li also holds multiple educational roles, including sponsoring the first Emory Genetics Interest Group at Emory College and School of Medicine to foster interest and attract intelligent students to join the growing field of medical genetics! Her research interests are primarily devoted to exciting clinical trials for genetic/metabolic diseases, and she is the principal investigator for multiple Phase I/II and III clinical trials. She is also interested in new gene discovery and better defining the phenotype of rare genetic diseases.On This Episode We Discuss:Symptoms that would warrant immediate genetic testing after birthStarting with whole genome sequencing (WGS) versus exomeOther tests that are useful for babies in the NICU beyond the genomeHow laboratories are maximizing the genome data for babies in a medical crisisSamples used for urWGS (ultra rapid WGS) and newborn screeningTrio testing with parents to rule out variants of being causative of symptomsurWGS minimizing healthcare costsWhy timing is so important for babies in the NICUHow results from urWGS can influence treatment plansHow projects like Project Baby Bear and Project Baby Deer are paving the way for whole exome sequencing as part of newborn screening Here is an interesting article from PerkinElmer about expanding into ultrarapid whole genome sequencing. During the interview Kira mentioned two episodes about the Telomere to Telomere Consortium which officially finished the complete human genome sequence in 2022. Dr. Eric Green shares his expertise in Episode 183 followed by Dr. Miga and Dr. Phillippy in Episode 184. Stay tuned for the next new episode of DNA Today on Friday, March 17th when muscular dystrophy experts Dr. Louise Rodino-Klapac (from Sarepta) and Livija Medne (Children's Hospital of Philadelphia aka CHOP) share their expertise specifically about limb-girdle muscular dystrophy. New episodes are released every Friday. In the meantime, you can binge over 225 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. Our Outreach Intern is Sanya Tinaikar. Our Social Media Intern is Kajal Patel. And our Graphic Designer Ashlyn Enokian.See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com. Surely you have heard of whole genome sequencing, but what about rapid and ultra-rapid whole genome sequencing? This is an emerging method of diagnosing genetic conditions for quick management. PerkinElmer Genomics offers this incredibly valuable test, which can be life saving for ill babies and kids. You can visit perkinelmergenomics.com for more information. (Sponsored)If you've been listening to DNA Today for a while, you probably know I am also a full time prenatal genetic counselor. Between that job, this podcast, and being a producer/host of other podcasts, I am pretty busy! To keep my energy up and stay productive I drink a decent amount of coffee. The new coffee I'm drinking is from Four Sigmatic. I'm really picky about my coffee, it's got to be bold, not watery. And I've been really happy with Four Sigmatic. Here's the difference from other coffees, it includes mushrooms, which I know sounds bizarre. I will admit I was hesitant, but you get health benefits and don't taste it. I like the immune system boost, as I often get sick in the winter months. So we teamed up with Four Sigmatic to get you 30% off using promo code “DNATODAY” redeem it at FourSigmatic.com, again that's FourSigmatic.com using code “DNATODAY” for 30% off! And let me know if you like it too! (Sponsored)I've enjoyed recording a few episodes about epigenetics, one of the interviews where I learned the most was with the Diagnostic Labs at the Greenwood Genetic Center. They taught me about EpiSign which is a novel clinically validated test that analyzes methylation. I just learned that since this episode in 2021, verison 4 of EpiSign has been released which has expanded to include over 70 conditions. If you are attending ACMG this month stop by booth 607 to chat with Greenwood Genetics. In the meantime brush up on your epigenetics by listening to Episode #145 of DNA Today and visit GreenwoodGeneticCenter. (Sponsored)Which muscular dystrophy causes weakness of the muscles typically starting around the hips and shoulders? That would be limb girdle muscular dystrophy, or LGMD. LGMD is a group of neuromuscular diseases caused by mutations in genes responsible for proteins critical for muscle function, regulation, and repair1-3. Sarepta is a global biotechnology company working on engineering precision genetic medicine with the goal of changing the lives of people living with rare muscular dystrophies. Their multi-platform Precision Genetic Medicine Engine includes gene therapy, RNA and gene editing approaches. Oh that reminds me, ACMG is in March and Sarepta will be at booth 504. You can also head over to limbgirdle.com to learn more. (Sponsored) 1. Murphy AP and Straub V. J Neuromusc Dis. 2015;2(suppl. 2):S7-S19.2. Liewluck T and Milone M. Muscle Nerve. 2018;58(2):167-77.3. McNally EM. The Sarcoglycans. In: Landes Bioscience. 2000–2013.

President Biden recently signed into law the FDA Modernization Act 2.0, new legislation that ends the FDA's mandate that all drugs be tested on animals prior to human clinical trials. The new law doesn't prohibit animal testing, but it does give companies the choice of whether to conduct animal experiments or not, and could lead to many fewer animals being used as test subjects.  If we don't use animals as test tubes prior to human clinical trials, what should we use? Emulate claims it has the answer. The organ-on-a-chip company's CEO Jim Corbett testified before Congress in favor of the new legislation and says his company's products deliver much more reliable data than does animal experimentation.  And why shouldn't it? We all know that rats (the most popular animal on whom to experiment) have pretty different biologies than humans. For example, people with pet rats are regularly warned not to give their rats onions since it can sicken them. We all know dogs are apparently not supposed to eat chocolate. Yet humans do just fine eating these foods that are toxic to rats and dogs.  So what if we could test on actual human cells that have been placed on chips which mimic the functions of a human body? In this episode, Jim discusses Emulate's technology, its promise to slash the number of animals used for testing while delivering safe drugs to market more quickly, who opposes their efforts, and where this is all leading us.  Emulate so far has raised a whopping quarter-billion dollars of venture capital investment, so someone believes that these folks are onto something big. Time will tell, and for now, their CEO will tell you the Emulate story. Discussed in this episode Emulate was birthed from Don Ingber's lab at Harvard with funding from DARPA Fast Company and WIRED on Emulate's work. Nature Communications Medicine Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) Science Translational Medicine Reproducing human and cross-species drug toxicities using a Liver-Chip (2019) Jim recommends the book Endurance to would-be startup founders Jim credits the Center for a Humane Economy with leading the passage of the FDA Modernization Act 2.0. More about Jim Corbett Jim Corbett has served as a leader of successful international businesses across diverse sectors, including biotechnology, medical imaging, analytical instruments and in vitro diagnostics. His experience ranges from Fortune 100 companies to entrepreneurial start-ups.  Until becoming the CEO of Emulate, he served in leadership roles at PerkinElmer during an 11-year tenure, including Executive Vice President and President of Discovery & Analytical Solutions. His other roles at PerkinElmer included President of Diagnostics & Life Sciences, Senior Vice President of Life Sciences Solutions, and Vice President of North America Genetic Screening. Prior to PerkinElmer, Corbett was President of ViaCell, Inc. which was acquired by PerkinElmer in 2007. Previously, he co-founded CADx Systems, a company focused on the oncology market, where he held the position of Executive Vice President and Director with responsibility for worldwide sales and marketing, technical support and business development. Following the 2004 acquisition of CADx by iCAD, Inc., he was named Chief Commercial Officer.  In addition, Corbett worked for Abbott Laboratories for 14 years in a variety of sales and marketing positions including Worldwide Marketing Manager for Abbott Diagnostics Immunoassay Systems and Region Manager for Abbott Diagnostics. Corbett holds a Bachelor of Science from The University of Massachusetts, Amherst.

This is the latest episode of the free DDW podcast, “Finding the right cancer drug with high-content screening”. It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW. In the article, Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct Professor in Cell and Molecular Biology, and Amanda Jones, Life Science Research Strategy Leader at PerkinElmer explain how functional precision medicine using ex vivo drug testing and HCS on patient-derived 3D cancer cell cultures shows promise for improving individual's treatment journey.

This week we welcome the President of BioSignal2, Inc Roger Bossé, Ph.D., to discuss using technologies based on Lanthanides emission (TRF, TR-FRET, LOCI) to perform ultrasensitive assays. Bosse is a leading expert on a wide range of detection technologies and applications that work in conjunction with microplate readers.Key Learning Points:What lanthanides are and how they can be used for assaysThe type of research lanthanide-based assays are ideal forWhat researchers need to know to use lanthanide-based assays for researchThe future advancement of lanthanide-based assays technologyLearn more about our BioSignal2 Inc. by visiting: http://www.biosignal2.com/About Roger Bosse:Bosse was the key individual that commercialized and developed the unique screening reagent platform “AlphaScreen” at PerkinElmer. He then expanded its breadth and scope to cover many applications in drug discovery and life sciences in general. Roger is highly skilled at assay design and development for early drug discovery efforts and has extensive cell signaling expertise. Our Sponsor for this EpisodeTheWell Bioscience – developer of VitroGel, a next-generation xeno-free 3D extracellular matrix (ECM), enables scientists to shift from 2D to 3D cell culture and help drive innovations for precision medicine, cell therapy and biomanufacturing by getting faster and more accurate data than animal-based systems.Learn more about TheWell Bioscience by visiting:www.thewellbio.comStay connected with SLASOnline at www.slas.orgFacebookTwitter @SLAS_OrgLinkedInInstagram @slas_orgYouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.  For more information about SLAS, visit www.slas.org.SLAS publishes two peer-reviewed and MEDLINE-indexed scientific journals, SLAS Discovery and SLAS Technology. For more information about SLAS and its jourUpcoming SLAS Events: SLAS2023 International Conference and Exhibition February 25 - March 1, 2023 San Diego, CA, USA SLAS 2023 Building Biology in 3D Symposium 20-21 April 2023 Cambridge, United Kingdom SLAS Europe 2023 Conference and Exhibition 23-26 May 2023 Brussels, Belgium

The brain's intractable nature makes neurodegenerative disorders challenging to study, but modern assays and technologies give scientists a fresh look at this complex organ. In this episode, Niki Spahich from The Scientist's Creative Services Team spoke with Erdem Gültekin Tamgüney, a professor in the Institute of Physical Biology at Heinrich Heine University Dusseldorf, about technologies driving modern neuroscience research and his own work exploring the link between ischemic stroke and Parkinson's disease. LabTalk is a special edition podcast produced by The Scientist's Creative Services Team, where we explore topics at the leading edge of innovative research. This month's episode is sponsored by PerkinElmer.

Learn about a genetic disorder called duchenne muscular dystrophy! We explore the genetics of DMD and treatments available with two experts in the field.We're joined by genetic counselor, ​​Ann Martin, who serves as the VP of Community Research and Genetic Services at Parent Project Muscular Dystrophy. Our other guest is world-renowned geneticist Dr. Madhuri Hegde from PerkinElmer Genomics. She is the Senior Vice President and Chief Scientific Officer of Global Lab Services at PerkinElmer. You may remember her from Episode 177 of DNA Today, which was a really fun episode where we geeked out on the power of whole genome sequencing!Sick of Zoom conferences? The Connecticut Genetic Counselors Association's first conference is in person! Jackson Laboratory is hosting us on Friday, October 14th in Farmington, CT. Our host, Kira Dineen, will be the moderator for Roe v. Wade Panel where we will be discussing the implications for practicing in a safe harbor state. Other presentation topics include polygenic risk scores, inclusive practice for LGBTQIA+ patients, and billing/credentials. We also built in networking time so we can all chat and get to know each other. Register here!On This Episode We Discuss:DMD average age of onset, symptoms, and symptom progressionDMD prevalence and inheritanceWhy it's important for people to be offered carrier screening before they are trying to conceiveReproductive options for people who are carriers of DMDWhat symptoms carriers of DMD are at risk forGetting the right testing for DMDCurrent treatment approaches for DMD (EMFLAZA)Ongoing clinical trialsPPMD's guides for caregivers of newly diagnosed peoplePerkinElmer Genomics' free testing program, DeCode Duchenne If you're interested in learning more about Decode Duchenne, the free genetic testing, counseling, and education program offered through a joint partnership between PerkinElmer Genomics and Parent Project Muscular Dystrophy, visit their website.We'd also like to feature a paper authored by one of our guests, Dr. Madhuri Hegde, about a single NGS-based assay that is highly sensitive for ​​diagnostic testing for DMD and is also suitable for confirmatory testing for newborn screening for DMD.Keep up with our guests on social media! Follow Parent Project MD on Twitter, Facebook, and Instagram, Dr. Maduri Hegde on Twitter, and PerkinElmer Genomics on Twitter and Facebook. If you found today's episode topic interesting and you want to learn more about DMD, we also chatted with Rich Horgan of Cure Rare Diseases whose brother has DMD in Episode 156!Stay tuned for the next new episode of DNA Today on September 16th 2022, where we'll be joined by Effie Parks of Once Upon A Gene Podcast to discuss CTNNB1 Syndrome! New episodes are released on Fridays. In the meantime, you can binge over 200 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com. Support for DNA Today comes from the People for The Ethical Treatment of Animals (also known as PETA), whose scientists have developed the research modernization deal, a strategy to phase out ineffective experiments on animals with high-tech, state-of-the-art research. PETA has collected an abundance of evidence demonstrating that the use of animals in biomedical research hinders scientific progress and puts patients at risk. Learn more at PETA.ord/NewDeal.TrakGene has designed a genetics electronic health record. Here's what it features: pedigrees, demographic data, genetics information, risk tools, and sophisticated reporting, all within a clinician designed workflow. It integrates with other clinical genetic software, databases, and hospital information systems to maintain accurate patient records.Go check it out at TrakGene.com. And keep your eye out for our full episode interviews with TrakGene coming soon to DNA Today.

Medical Device leader and innovator Anthony Fernando discusses the future of robotic surgery, regulations, and cybersecurity. Anthony Fernando is President and CEO of Asensus Surgical, a company that is reimagining how surgeries are being done. Anthony is a veteran of the medical device industry, having held key positions at Stryker, Becton Dickinson & Company, PerkinElmer, and more.

The Dow gained 27 points after yesterday's surge, and Jim Cramer's guiding investors through the market's latest moves. Next, PerkinElmer CEO Prahlad Singh joins Cramer to discuss earnings, the changes in the science and diagnostic equipment market post-COVID, and the company's outlook going forward. Then, Realty Income CEO Sumit Roy talks to Cramer about the company's second quarter, the company's commitment to consistently making sure investors are receiving capital monthly, and their tenant portfolio. Plus, Darling Ingredients CEO Randy Stuewe.

On this week's podcast, we have three conversations: with Ian Smith, sales director at PFF; Dr Ardythe Morrow, Professor of Epidemiology and Pediatrics at the University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center; and Wopke Beukema, senior manager R&D at PerkinElmer, Inc.

World-renowned medical geneticist Dr. Madhuri Hegde, joins the show to explore whole genome sequencing (WGS). She is the Senior Vice President and Chief Scientific Officer of Global Lab Services at PerkinElmer, a global leader in genetic and genomic testing focused on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Dr. Hegde is also a board certified diplomate in clinical molecular genetics by the American Board of Medical Genetics, and an ACMG Fellow. Previously, she was the Executive Director of Emory Genetics Laboratory. She received a B.Sc. and M.Sc. from the University of Bombay and a Ph.D. from the University of Auckland. She completed postdoctoral studies at Baylor College of Medicine.On This Episode We Discuss:The difference between WES and WGSHow WGS differs between laboratories The frequency at which WGS reveals an additional condition/disorder that the ordering providers were not expectingSituations in which trio testing is helpful for WGSPrenatal WGSThe future of newborn screeningWGS for hereditary cancer syndromesHow people learn more about PerkinElmer's WGSLearn more about WGS at PerkinElmerGenomics.com and follow them on Twitter, Facebook, and LinkedIn. Be sure to follow our guest, Dr. Madhuri Hegde, on LinkedIn.Head over to our social media to enter our giveaway! Search “DNA Today” on Instagram and Twitter. Go to our host's posts on LinkedIn by searching “Kira Dineen”. There you can enter to win “Modern Clinical Molecular Techniques”. Dr. Hedge is one of the editors. An earlier edition was one of Kira's textbooks in undergrad! Stay tuned for the next new episode of DNA Today on April 1st 2022, where we'll be discussing single-cell spatial genomics with Vizgen! New episodes are released on Fridays. In the meantime, you can binge over 175 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com. Curious to take a peek inside your body's drug response? Then you should check out Picture Genetics' PGx Test. Powered by clinical laboratory Fulgent Genetics, Picture's PGx Test is easy to order and understand, with hassle-free clinician involvement and good looking reports! Plus you are fully supported through live chats, emails and genetic counseling. To order your Picture PGx test kit, visit picturegenetics.com and use code “DNATODAY” for 25% off and free-shipping! Get actionable genetic insights today to benefit your health tomorrow. Check out Picture Genetics' interview about pharmacogenomics with their Director of Genetic Counseling, Gregory Kellogg on Episode #174 of DNA Today! (SPONSORED)Have you heard of the Blueprint Genetics My Retina Tracker Program? This program offers eligible patients in the US no-cost comprehensive genetic testing and counseling for their inherited retinal degeneration. The My Retina Tracker Program Panel includes 351 genes, mitochondrial DNA, and non-coding variant assessment. Stay tuned for our interview with Blueprint Genetics about the My Retina Tracker Program and the patient registry on a future episode of “DNA Today”. In the meantime, you can learn more at BlueprintGenetics.com. (SPONSORED)Polygenic risk scores (or PRS) are a powerful way to identify an individual's risk of common disease by analyzing up to millions of genetic variants spread across the genome. Allelica has launched the first PRS test on the market to calculate ancestry-specific PRS for breast cancer, prostate cancer, coronary artery diseases, Type 2 Diabetes and Alzheimer's disease and deliver the results in a clinical-grade report. Order your test today at order.allelica.com. For 25% off AND free shipping, use code “DNATODAY” at checkout. Allelica: Empowering the next generation of clinical genomics. Check out Allelica' interview about PRS with co-Founder and CEO Giordano Bottà on Episode #168 of “DNA Today”! (SPONSORED)

Cynthia A. Fisher is the Founder and Chairman of PatientRightsAdvocate.org, a nonprofit advocacy organization representing American healthcare consumers – patients, employers, unions, and workers – seeking to greatly reduce the cost of healthcare and coverage through systemwide price transparency and creation of a functional, competitive marketplace in healthcare. Cynthia is a public company Director of The Boston Beer Company (SAM) and Easterly Government Properties, Inc. (DEA). Cynthia founded the pioneering cord blood stem cell banking company, ViaCord, Inc., in 1993 and served as CEO, offering the novel biomedical service with price, quality, and outcomes transparency. In 2000, Cynthia co-founded the cellular medicines company, ViaCell, Inc, of which ViaCord became a division. She served as President and on the Board of Directors. ViaCell went public, was acquired by PerkinElmer, and exists today under the ViaCord brand. Cynthia co-founded and is Chairman of FitMoney.org, providing schools and teachers curriculum for K-12 financial literacy. She is a Director of the National Park Foundation and formerly served on the Board of Water.org. She is the former Speaker of the House of Representatives' appointee to the federal Health Information Technology Advisory Committee. Cynthia holds an MBA from Harvard Business School as well as an Honorary Doctorate of Science and BS in Biophysics from Ursinus College. Unlock Bonus content and get the shows early on our Patreon Follow us or Subscribe: Apple Podcasts | Google Podcasts | Stitcher | Amazon  | Spotify --- Show notes at https://rxforsuccesspodcast.com/85 Report-out with comments or feedback at https://rxforsuccesspodcast.com/report Music by Ryan Jones. Find Ryan on Instagram at _ryjones_, Contact Ryan at ryjonesofficial@gmail.com  

For more details, visit #DrGPCR​​​ Podcast Episode #57 page: https://www.drgpcr.com/episode-57-with-dr-peter-robert-banks/ ------------------------------------------- About Dr. Peter Robert Banks Peter Banks is currently the Scientific Director at BioTek Instruments, now a part of Agilent. His responsibilities include the management of the company's applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting life sciences. Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer's BioPharma R&D program and Chair of the company's Scientific Advisory Board. Prior to experiences at PerkinElmer and BioTek, Banks was an Assistant Professor in Analytical Chemistry at Concordia University, Montreal, Canada from 1994 to 1998. ------------------------------------------- Imagine a world in which the vast majority of us are healthy. The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. To build our #GPCR Ecosystem, we created various enabling outlets. For more details, visit our website http://www.DrGPCR.com/Ecosystem/. ------------------------------------------- Are you a #GPCR professional? - Register to become a Virtual Cafe speaker http://www.drgpcr.com/virtual-cafe/ - Subscribe to our Monthly Newsletter http://www.drgpcr.com/newsletter/ - Listen and subscribe to #DrGPCR Podcasts http://www.drgpcr.com/podcast/ - Support #DrGPCR Ecosystem with your Donation. http://www.drgpcr.com/sponsors/ - Reserve your spots for the next #DrGPCR Virtual Cafe http://www.drgpcr.com/virtual-cafe/ - Watch recorded #DRGPCR Virtual Cafe presentations: https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw - Bring in a #GPCR Consultant http://www.drgpcr.com/consulting/ - Share your feedback with us: http://www.drgpcr.com/audience-survey/ - Become a #DrGPCR Ecosystem Member http://www.drgpcr.com/membership/

Follow me to see #HeadsTalk Podcast Audiograms every Monday on LinkedIn. Episode Title:-

On this week's podcast, we have conversations with Wopke Beukema, senior manager R&D at PerkinElmer, Inc.; Miguel Freitas, PhD, vice president of scientific affairs, and Kristie Leigh, registered dietitian nutritionist and senior manager of scientific affairs at Danone North America; and Donald Moore, executive director of Global Dairy Platform.

The latest free-to-listen DDW podcast episode is titled “Recipe for success: collaboration in drug discovery”.  It covers three articles: “Why collaboration matters and how to make it a success”; “Platform biotechnologies and the art of collaboration”; and “Cell painting: a vibrant future for phenotypic drug discovery”.   In the first article, Matthew A. Clark, Chief Executive Officer, X-Chem, spoke to Lu Rahman about the company's experience of collaboration and how it enables innovation, flexibility and problem-solving. In the second, Benedict Cross, Chief Technology Officer at Phoremost, explains that despite its competitive nature, the drug discovery sector has embraced collaboration successfully. In the third article, Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content Screening Software Product Manager, PerkinElmer discuss how cell painting is being applied today in drug discovery and the current technical limitations and challenges. 

Originally Published as The Niche PodcastBeiGene's oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party Find out more athttps://thenichepod.comStory Referenceshttps://tinyurl.com/Niche-069-1https://tinyurl.com/Niche-069-2https://tinyurl.com/Niche-069-3https://tinyurl.com/Niche-069-4https://tinyurl.com/Niche-069-5https://tinyurl.com/Niche-069-6https://tinyurl.com/Niche-069-7https://tinyurl.com/Niche-069-8Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodsonLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

  In this episode, the team is joined by Dr Toby Astill who is PerkinElmer's global Market Manager Leader.   We explore what happens when you cross cannabis with robotics, and Toby provides an overview of the benefits of automating laboratory testing and PerkinElmer's new QS Works 420 workflow. Opinionated Science is Technology Networks' homemade podcast, where our team of scientists-turned-journalists cut out the chewy jargon and serve up slices of the most fascinating stories from the world of science. Expect a new Opinionated Science every other Friday.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with JaeB Kim, Managing Director at Samsung Biologics America. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with JaeB, covering: A year at one of the largest and fastest-growing CDMOs in the world. Growing a US presence within the thriving biopharma cluster in San Francisco Bay with ambitious plans for future expansion. The need for industry to ‘give' in order to ‘take' from innovation in academia, along with the pivotal role that collaboration has played during the pandemic. How Covid-19 has ‘tested the system' from R&D to logistics and patient supply and how this will enable the sector to be better prepared for a more orchestrated response to future pandemics. JaeB is a senior life sciences professional with 15 years of experience in biotech and biologics manufacturing. With an MBA and a PhD in Cancer Biology, he worked for PerkinElmer before joining global CDMO giant Samsung Biologics in 2020. JaeB is also an Adjunct Assistant Professor at Michigan State University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Analyzing the meat industry is PerkinElmer's mission, using the latest data techniques to improve food safety and quality. In this special podcast, David Honig talks about the challenges of analysis in the meat industry and the tools PerkinElmer uses to overcome them. Sponsored by:

In the season's final episode, John Harvey, founder and CEO of Southern Photonics, shares his journey from nuclear physics to biophotonics, and from lasers to test and measurement equipment. The state of the photonics industry in Australia and New Zealand is among the points of discussion. Rohit Bhargava, Founder Professor of Engineering and director of the Cancer Center at the University of Illinois at Urbana-Champaign, talks about a new technique for solid-tissue imaging that relies on the microscopic detection of chirality. Sponsored by: PerkinElmer - www.PerkinElmer.com All Things Photonics is produced by Photonics Media and airs biweekly, on Tuesdays. Find links to the stories mentioned on our website, www.photonics.com/podcast. The podcast was a shortlisted finalist in two categories - Best Science & Medical Podcast and Best Technology Podcast - for The Publishers Podcast 2021 Awards. Season 1 received an Honorable Mention for excellence in engaging content from the 2020 Folio Eddie Awards.

In this episode, our host Wayne Blonski and his co-host, Anne-Catherine Breton, discuss the different types of sample preparation. How do you know which technique to choose for mining samples? Is there a universal method for preparing samples prior to optical spectroscopy analysis? They will give you tips and tricks on which techniques to use! For any questions regarding the mining samples, please contact Anne-Catherine at anne-catherine.breton@agilent.com.

The Dow closed up 19 points while the S&P 500 posted a record close and Jim Cramer is guiding investors through the biggest news of the day. Then, could a pet retail stock help you become the "Woof" of Wall Street? Chewy CEO Sumit Singh checks fresh off earnings. Next, PerkinElmer CEO Prahlad Singh is digging deeper into where the life sciences stock is heading in a post-pandemic world. Plus, J.P. Morgan Retail Analyst Matt Boss.

Laser-induced breakdown spectroscopy is the technology behind a newly developed forensic technique for tire chemical analysis. University of Central Florida's Matthieu Baudelet, who introduced the method in a recent Applied Spectroscopy paper, explains the approach and how it is poised to enhance crime scene investigation. Pierre Türschmann, CEO of Interherence, talks about how the company is working to resolve the bottleneck of reproducibility in microscopy. Sponsored by: PerkinElmer - www.PerkinElmer.com All Things Photonics is produced by Photonics Media and airs biweekly, on Tuesdays. Find links to the stories on our website, www.Photonics.com/podcast. The podcast was a shortlisted finalist in two categories - Best Science & Medical Podcast and Best Technology Podcast - for The Publishers Podcast 2021 Awards. Season 1 received an Honorable Mention for excellence in engaging content from the 2020 Folio Eddie Awards.

In this episode, host Jean-Louis Cabral has a very dynamic discussion with our guest Shawn McFadden from Ryerson University on the tips & tricks of how to ensure engagement with trainees remotely for improved learning experience. Check out their successful and failed experiences and learn more about modern learning! Shawn also introduces an interesting project he's been working on focusing on indigenous medicine and wild ginseng benefits.   If you're working within the industry or within academia and are interested in improving your current training programs, Shawn is reachable at smcfadde@ryerson.ca.   Want to suggest a future topic for discussion? Email the host at jean-louis.cabral@agilent.com with your idea. Thanks for listening and please feel free to share this great new resource!  

Western New York (specifically, the city of Rochester) is a globally recognized hub for optics, photonics, and imaging innovation. From titans Kodak and Xerox to an industry’s reemergence from a global pandemic, New York Photonics’ Executive Director Thomas Battley discusses how one industry (specifically, one cluster) blends contributions from industry, academia, and government to drive economic growth and scientific progress. Sponsored by: PerkinElmer - www.PerkinElmer.com All Things Photonics is produced by Photonics Media and airs biweekly, on Tuesdays. Find links to the stories mentioned on our website, www.Photonics.com/podcast. The podcast has been named a finalist in two categories - Best Science & Medical Podcast and Best Technology Podcast - for The Publishers Podcast 2021 Awards. Season 1 received an Honorable Mention for excellence in engaging content from the 2020 Folio Eddie Awards.

Greg Quarles, former OSA chief scientific officer and current CEO of Applied Energetics, takes us beyond the defense sector and the combatting of threats along the electromagnetic spectrum, outlining current applications in directed energy. Tom Nugent, CTO and co-founder of PowerLight Technologies, talks optical power beaming - a technology that is closer than you think. Sponsored by: PerkinElmer - www.PerkinElmer.com All Things Photonics is produced by Photonics Media and airs biweekly, on Tuesdays. Find links to the stories mentioned on our website, www.Photonics.com/podcast. The podcast has been named a finalist in two categories - Best Science & Medical Podcast and Best Technology Podcast - for The Publishers Podcast 2021 Awards. Season 1 received an Honorable Mention for excellence in engaging content from the 2020 Folio Eddie Awards.

Durant cette épisode, notre animatrice Anne-Catherine Breton s'entretient avec deux représentants de service, Geneviève Bernier et Vladimir Merdzan. Ils abordent les nombreux défis surmontés depuis le début de la pandémie et partagent leurs expériences quotidiennes en tant que représentant de service sur les routes du Canada. Ils nous font également part de leurs coups de coeur culinaires durant leurs périples à travers notre beau pays et les régions de notre belle province!

Durant cette épisode, notre animatrice Anne-Catherine Breton s'entretient avec deux représentants de service, Geneviève Bernier et Vladimir Merdzan. Ils abordent les nombreux défis surmontés depuis le début de la pandémie et partagent leurs expériences quotidiennes en tant que représentant de service sur les routes du Canada. Ils nous font également part de leurs coups de coeur culinaires durant leurs périples à travers notre beau pays et les régions de notre belle province!

In this episode, the team is joined by Ariel Bohman, an application scientist at PerkinElmer. They discuss the different types of microplastics and how they are affecting everything from the food we eat to the corals in our oceans.    

Dans ce premier épisode, le directeur des ventes spectroscopie d'Agilent Canada, Jean-Louis Cabral vous présente ces co-animateurs Anne-Catherine Breton et Jordan Plenzich. Tous les membres de l'équipe sont heureux de vous accueillir pour cette nouvelle série de balados sur la spectroscopie (et autres sujets scientifiques) par et pour les scientifiques canadiennes et canadiens, mais ouverts sur le monde!

In this introduction episode, Agilent Canadian spectroscopy sales manager Jean-Louis Cabral introduces his co-hosts Bastian Georg, Clint Walker, and Wayne Blonski. All members of the team are very excited to welcome you to this new series of podcasts on spectroscopy (and other scientific topics) by and for Canadian scientists, also open to the world!

Nach dem Bitcoin-Hype 2017 war es längere Zeit ruhig gewesen um Kryptowährungen. Aber mit dem fulminanten Kursanstieg über den Jahreswechsel ist das Thema wieder im Fokus der breiten Öffentlichkeit angekommen. Die Marktkapitalisierung nimmt rasant zu, die Kursschwankungen auch. Wie funktioniert überhaupt eine Kryptowährung? Was ist eine Blockchain und welche Anwendungsgebiete gibt es? Und ist der Bitcoin nicht längst viel zu teuer? Diese Fragen möchten wir in diesem Podcast diskutieren. Im Wochenrückblick schauen wir kurz auf Gold und Silber, sprechen über den Rauswurf des CEO beim Chip-Hersteller Intel und die Übertreibungen am Markt. Sinnbild dafür ist Tesla. Elon Musk hat mal wieder für eine Sensation gesorgt, in dem er mit einem einzigen Tweet für über 1.000% Kursgewinn bei einem Penny Stock gesorgt hat. Die nächsten Wochen und Monate könnten turbulent werden. Infos und Links Wenn dir der Podcast gefällt, empfehle uns gerne weiter in deinem Freundeskreis, abonniere unseren Kanal oder schreib uns eine positive Bewertung. Außerdem hast Du die Möglichkeit, uns auf www.promilleprozente.de monatlich wiederkehrend mit einem kleinen finanziellen Beitrag deiner Wahl zu unterstützen. Auch kleine Einmalzahlungen per PayPal an fanpost@promilleprozente.de sind eine große Hilfe. Die mit (*) markierten Links sind Affilliate Links, bei denen wir für eine Kontoeröffnung eine Provision erhalten. Vielen Dank dafür! Themen in dieser Folge mit Minutenangaben: 05 min: Gold & Silber 08.30 min: Intel 11 min: Gold & Silber 26 min: Elon Musk und die Börsen Euphorie 19 min: Was ist eine Kryptowährung? 30 min: Wie funktioniert die Blockchain? 38 min: Welche Kryptowährungen gibt es? 62 min: Wie kann ich Kryptos handeln? 67 min: Aktien der Woche - Hyundai und Plug Power 74.30 min: Update im Musterdepot - Play Magnus (A2QDZX), PerkinElmer (850943), Shop Apotheke Europe (A2AR94), Etsy (A14P98) Basiswissen zu Kryptos findest Du z.B. hier: https://youtu.be/2473NHJtdFA https://youtu.be/5nD-C7NL0PE https://youtu.be/H8AdJxXELp8 So handeln wir Aktien, ETFs und Optionsscheine handeln wir mit der kostenlosen App Trade Republic: https://financeads.net/tc.php?t=37121C274449894T* Kryptowährungen, Rohstoffe, Indizes oder CFDs handeln wir mit eToro und Kraken: https://financeads.net/tc.php?t=37121C106553660T* https://r.kraken.com/kmLEV* Weitere bekannte Krypto Börsen: https://bisonapp.com/ https://www.coinbase.com/de/ https://www.binance.com/de Kontakt Mail: fanpost@promilleprozente.de Instagram: www.instagram.com/promilleprozente Web: www.promilleprozente.de --- Send in a voice message: https://anchor.fm/promilleprozente/message

Nevin Perera is Research & Development manager for PerkinElmer where he and his team have developed a range of ELISA immunoassays including Solus One Salmonella, Solus One Listeria, and Solus One E.coli. Nevin’s career started at the University of Birmingham – in the UK - where he studied for a B.Sc. (Hons) in Microbiology before transitioning into a M.Sc. in Toxicology and a Ph.D. in Biochemistry that looked into the regulation of Phospholipase C in yeast under different environmental and chemical stresses. He continued his academic career at the Department of Cell Signalling and Immunology, University of Dundee; carrying out Post-doctoral research into the regulation of the tumor suppressor gene PTEN for five years, finishing with ten peer-reviewed journal publications. Upon leaving academia, Nevin has focused his career in ELISA and LFD development, doing outstanding work at Merck Millipore, Mediawatch Plc. and now PerkinElmer. In this BONUS episode of Food Safety Matters, we speak to PerkinElmer's Nevin Perera about: Pressure on the food industry regarding the critical need for rapid and accurate pathogen detection How PerkinElmer targeted the trifecta of rapid, specific, and sensitive assays for food matrices and environmental surfaces in alignment with FSMA Comparing methods, molecular, culture, and immuno-based Optimizing workflow parameters Solus One global validations and certifications Meeting the challenges of troublesome matrices Presenting Sponsor PerkinElmer Learn more about Solus One:  Salmonella, Listeria, E.coli O157 Learn more about Solus One for Environmental Monitoring

Es gab wohl selten eine Pressemitteilung, die weltweit die Aktienmärkte derart bewegt hat. Die Studiendaten von BioNtech und Pfizer zur überraschend hohen Wirksamkeit des Impfstoffes gegen Covid-19 haben zu großen Kursauschlägen geführt - nach oben und nach unten. Die Karten werden nun voraussichtlich neu gemischt. Die Corona-Profiteure der vergangenen Monate wurden größtenteils abgestraft, arg gebeutelte Branchen wie Touristikunternehmen, Fluggesellschaften oder Kinobetreiber gingen durch die Decke. Aber ist diese Entwicklung wirklich von Dauer? Wir erklären euch die wohlmöglich anstehende Sektorrotation und den Unterschied zwischen Growth- und Value-Aktien. Es zeichnet sich ab, dass bereits in Kürze Impfstoffe verschiedener Firmen in großen Mengen zur Verfügung stehen werden. Dennoch werden nicht alle Unternehmen und Branchen gleichermaßen davon profitieren. Außerdem werfen wir einen Blick auf das neue Freihandelsabkommen in Asien, die Pläne der chinesischen Regierung zur Regulierung der heimischen Tech-Industrie und das vermeintliche Comeback von Donald Trump zur Wahl 2024. Wenn dir der Podcast gefällt, empfehle uns gerne weiter in deinem Freundeskreis, abonniere unseren Kanal oder schreib uns eine positive Bewertung. Außerdem hast Du die Möglichkeit, uns auf www.promilleprozente.de monatlich wiederkehrend mit einem kleinen finanziellen Beitrag deiner Wahl zu unterstützen. Auch kleine Einmalzahlungen per PayPal an fanpost@promilleprozente.de sind eine große Hilfe. Vielen Dank dafür! Wir handeln mit der kostenlosen App Trade Republic und können diese sehr empfehlen. Sie ist nicht nur übersichtlich und benutzerfreundlich gestaltet, sondern berechnet lediglich eine Ordergebühr von 1€ pro Ausführung. Das ist im Vergleich zu anderen Online-Brokern sehr wenig. Wenn Du die App ausprobieren möchtest, freuen wir uns, wenn Du unseren Empfehlungslink nutzt. Damit hilfst Du dabei, dass der Podcast weiterhin wöchentlich erscheint: https://financeads.net/tc.php?t=37121C274449894T Über folgende Titel haben wir in der Folge gesprochen: Disney (WKN: 855686) / PerkinElmer (850943) / Hyundai (885166) / Volkswagen (766403) / Borussia Dortmund (549309) Mail: fanpost@promilleprozente.de Instagram: www.instagram.com/promilleprozente Web: www.promilleprozente.de Risikohinweis: Die genannten Aktien stellen keine Anlageempfehlung dar! Die Vortragenden informieren in diesem Podcast lediglich über ihre persönlichen Interessen und Investitionsentscheidungen. Jedes Investment sollte vorab gründlich abgewogen werden, insbesondere in Bezug auf Anlageerfahrung und Risikotragfähigkeit. Wir weisen ausdrücklich darauf hin, dass ein Kauf von Aktien oder anderen Finanzprodukten, die in diesem Podcast thematisiert werden, zum Totalverlust des eingesetzten Vermögens führen kann. Die Vortragenden übernehmen keine Haftung für entstandene Verluste. --- Send in a voice message: https://anchor.fm/promilleprozente/message

California Gov. Gavin Newsom announced Wednesday that the state has contracted with a diagnostics company to conduct up to 150,000 more COVID-19 tests a day.Under the contract, the state will build a testing laboratory and provide some testing equipment, such as supplies to collect and transport specimens, according to Health and Human Services Agency Secretary Dr. Mark Ghaly.The company, PerkinElmer, will process and report back test results within 48 hours, but the company will not collect the actual nasal swabs. That will happen at state testing sites.Dr. Wilma Wooten, San Diego County's public health officer, welcomed the deal, set to begin in eight to 10 weeks

The Dow closed down 86 points to start the week with the Nasdaq hitting a record high and Jim Cramer's here to help investors make sense of the day on Wall Street. Then, PerkinElmer CEO Prahlad Singh joins Cramer to break down the most recent quarter and the company's outlook going forward. Then, Cramer's taking a closer look at recent IPO KE Holdings, China's largest digital housing platform, and how the company might fare amid tensions between the U.S. and China. Plus, Cramer's exclusive with GrowGeneration CEO Darren Lampert.   Learn more about your ad choices. Visit megaphone.fm/adchoices

This week’s podcast is dedicated to some of the companies presenting new products or concepts related to the dairy industry at the recent virtual SHIFT20 event, put on by the IFT (Institute of Food Technologists).

How data and analytics can help solve regional problems and foster local development? Tom Verhelst, Program Director of the Regional Innovation Data Lab (RIDL) at Griffith University, says that it is by taking a holistic view of the locality through effective place-based analytics. Tom has made his presence felt across the humanitarian use of data science. Before joining Griffith University, Tom was the Associate Director R&D IT at UCB, which is among the top 30 global pharmaceutical companies, and Project Manager Professional Services, Informatics at PerkinElmer, a Fortune 500 company. In this episode, he gives a detailed view of how all that took place in terms of using data analytics, AI, and machine learning. Tom talks about why it is necessary to look deeply into the data sets of local metrics and the whole socio-cultural structure to solve regional problems specific to regional councils. He also explains why we need to create a safe space where businesses, government bodies, and other entities can share data to aggregate, anonymise, and use to drive regional public growth. More links about the guest LinkedIn Profile URL: https://www.linkedin.com/in/tom-verhelst-2932216/ Organisations: https://www.griffith.edu.au/griffith-business-school/policy-innovation-hub/regional-innovation-data-lab https://www.ridl.com.au/ In the News: https://news.griffith.edu.au/2019/12/03/five-griffith-financial-planning-guns-recognised-with-national-awards/ https://www.qcif.edu.au/index.php/news/483-qcif-and-aurin-support-griffith-s-regional-innovation-data-lab Research Papers: https://scholar.google.com/citations?user=_gDva7YAAAAJ https://www.researchgate.net/profile/Tom_Verhelst2 --- Send in a voice message: https://anchor.fm/analyticsshow/message

Microplastics, including polypropylene, are present in our oceans, on our beaches and even in bottled water. Ian Robertson from PerkinElmer investigates the scale and some solutions

Elissa Levin was one of the first genetic counselors to work in the direct-to-consumer sector, starting at DNA Direct (remember that?); she’s been at Illumina-spinoff Helix for about 3 years. Helix runs a DTC marketplace, offering an the all-purpose DNA test (exome plus microarray) that can be queried by any of their testing partners. Now Helix has partnered with PerkinElmer to produce a new entry for its own marketplace -- the PerkinElmer GenePrism test.

During a recent Uber ride, Madhuri Hegde's driver asked her what she did for a living. The chief scientific officer for laboratory services at PerkinElmer, she prepared to bore him with a description of the tests her company had developed—most recently to flag serious genetic disorders. Instead, he was intrigued. “Where can I get one of those?” he asked. For years, PerkinElmer has only offered that clinical test to doctors.

In this episode of Inspired Marketing we had the pleasure of learning from Richard Flaherty, Global Director of Marketing Services at PerkinElmer. Richard took on the challenge of doing a data clean up and creating a more efficient MarTech stack. He shares with us his process, challenges and what he learns about SalesForce. Listen and find out how you can implement some of the same changes in your organization.  

In this podcast, Marilyn Cox of the Oracle Marketing Cloud shares a case study of how PerkinElmer used marketing automation in conjunction with their events to provide a better customer experience …

In this podcast, Marilyn Cox of the Oracle Marketing Cloud shares a case study of how PerkinElmer used marketing automation in conjunction with their events to provide a better customer experience … This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

What's PerkinElmer been up to lately? From spy sattelites to medical screening procedures, we take a close look at the company. Learn more about your ad-choices at https://news.iheart.com/podcast-advertisers

How did two different divisions come together to form PerkinElmer? What does the company do? Learn more about your ad-choices at https://news.iheart.com/podcast-advertisers

Dairy processors are "taking a hardline to try to eradicate" adulterants, such as urea and melamine, from milk powder, PerkinElmer has claimed following the launch of its new DairyGuard milk powder analyzer.